HC Wainwright resumed coverage on Iterum Therapeutics
$ITRM
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright resumed coverage of Iterum Therapeutics with a rating of Hold
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/27/2021 | Sell → Hold | Gabelli & Co. | |
| 7/26/2021 | Buy → Neutral | HC Wainwright & Co. |
U.S. Commercial Launch of ORLYNVAHTM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that it entered into a Product Commercialization Agreement (the "Agreement") with EVERSANA Life Science Services, LLC ("EVERSANA") for the commercialization of the Company's approved product, ORLYNVAHTM. Pursuant to the Agreement, EVERSA
DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that Pfizer Inc. ("Pfizer") has agreed to extend the term for payment of the regulatory milestone payment of $20.0 million until October 25, 2029. "We are very pleased to announce that Pfizer has agreed to extend the due date for payment of the regulatory milestone associated with ORLYNVAH™'s approval by the FDA," said Corey Fishman, Iterum's Chief Executive Officer. "The $20.0 milli
--Preparing for Potential Launch of ORLYNVAHTM by Q4 2025-- --Extended Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, May 13, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31, 2025. "Based on pre-commercialization work completed to date, we expect to be able to launch ORLYNVAHTM for the treatment of uncomplicated urinary tract infections (uUTIs) by the fourth quarter of th
8-K - Iterum Therapeutics plc (0001659323) (Filer)
8-K - Iterum Therapeutics plc (0001659323) (Filer)
10-Q - Iterum Therapeutics plc (0001659323) (Filer)